Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A

SSZSE:301130
22.34
CNY
-0.64
(-2.79%)
-0.08EPS
2.18BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A carries a market capitalization of 2.18B, placing it among publicly traded companies globally. Its enterprise value stands at 2.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.18B
Enterprise Value2.02B

Share Statistics

As of September 30, 2026, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A has 76.49M shares outstanding.

Shares Outstanding76.49M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 11.09, and the price-to-book ratio stands at 2.51.

PS Ratio11.09
PB Ratio2.51
P/TBV Ratio3.11

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 10.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.02B versus a market cap of 2.18B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales10.35

Financial Position

As of September 30, 2026, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A maintains a current ratio of 3.47, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.52, indicating elevated leverage, while an interest coverage ratio of -17.66 demonstrates limited ability to service its debt obligations.

Current Ratio3.47
Quick Ratio2.38
Debt / Equity4.52
Debt / EBITDA-3.44
Interest Coverage-17.66

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A posted a negative return on equity (ROE) of -0.54, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.45, reflecting losses generated across the asset base. The company generates approximately 624,104.66 in revenue per employee across its workforce of 313.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.14 indicates how many times Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-0.54
Return on Assets (ROA)-0.45
Revenue Per Employee624,104.66
Employee Count313.00
Inventory Turnover2.14

Taxes

CNY

Over the twelve months ended September 30, 2026, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A recorded an income tax benefit of -4.74M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -11.18M and -4.77M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-4.74M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A's stock has declined approximately 31.47% over the past 52 weeks. The 50-day moving average sits at 26.49, while the 200-day moving average is 28.53.

52-Week Price Change-31.47%
50-Day Moving Average26.49
200-Day Moving Average28.53

Income Statement

CNY

Over the twelve months ended September 30, 2026, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A generated 195.34M in revenue and converted that into -4.77M in net income, yielding earnings per share of -0.08. EBITDA reached -11.81M, while operating income came in at -12.74M.

Revenue195.34M
Gross Profit139.63M
Operating Income-12.74M
Pretax Income-11.18M
Net Income-4.77M
EBITDA-11.81M
EBIT-11.81M
Earnings Per Share (EPS)-0.08

Balance Sheet

CNY

As of September 30, 2026, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A holds 229.54M in cash and equivalents against 40.59M in total debt, resulting in a net debt position of -37.75M. Total book value stands at 868.69M, with working capital of 238.00M providing operational flexibility.

Cash & Cash Equivalents229.54M
Total Debt40.59M
Net Debt-37.75M
Equity (Book Value)868.69M
Book Value Per Share11.36
Working Capital238.00M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-56.81M

Margins

Over the twelve months ended September 30, 2026, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A posted a gross margin of 71.48, reflecting its pricing power and cost economics. The operating margin of -6.52 and net profit margin of -2.44 provide insight into operational efficiency.

Gross Margin71.48
Operating Margin-6.52
Pretax Margin-5.72
Profit Margin-2.44
EBITDA Margin-6.05

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A paid dividends of 0.15 per share. The dividend payout ratio of -143.43 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.56, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A shareholders.

Dividend Per Share0.15
Payout Ratio-143.43
Shareholder Yield0.56

Scores

As of September 30, 2026, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A has an Altman Z-Score of 9.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score9.15